Hemato (May 2021)

A Score for Predicting Freedom from Progression of Children and Adolescents with Hodgkin Lymphoma

  • Valli De Re,
  • Laura Caggiari,
  • Maurizio Mascarin,
  • Mariangela De Zorzi,
  • Caterina Elia,
  • Ombretta Repetto,
  • Lara Mussolin,
  • Marta Pillon,
  • Paola Muggeo,
  • Salvatore Buffardi,
  • Maurizio Bianchi,
  • Alessandra Sala,
  • Luciana Vinti,
  • Piero Farruggia,
  • Elena Facchini,
  • Egesta Lopci,
  • Emanuele S. G. d’Amore,
  • Roberta Burnelli,
  • with the A.I.E.O.P. Consortium

DOI
https://doi.org/10.3390/hemato2020016
Journal volume & issue
Vol. 2, no. 2
pp. 264 – 280

Abstract

Read online

Several studies have examined the prognostic performance of therapeutic groups (TG) and early responses to therapy on positron emission tomography/computed tomography (PET/CT) in children and adolescents with classical Hodgkin lymphoma (cHL); less research has been performed on molecular parameters at diagnosis. The aim of the present study was to devise a scoring system based on the TG criteria for predicting freedom from progression (FFP) in 133 patients: 63.2% males; 14 years median age (interquartile range (IQR) 11.9–15.1); with cHL (108 nodular sclerosis (NS) subtype) treated according to the AIEOP LH-2004 protocol; and median 5.55 (IQR 4.09–7.93) years of follow-up. CHL progressed or relapsed in 37 patients (27.8%), the median FFP was 0.89 years (IQR = 0.59–1.54), and 14 patients (10.5%) died. The FPR (final prognostic rank) model associates the biological HLA-G SNP 3027C/A (numerical point assigned (pt) = 1) and absolute neutrophil count (>8 × 109/L, pt = 2) as variables with the TG (TG3, pt = 3). Results of FPR score analyses for FFP suggested that FPR model (Kaplan–Meier curves, log-rank test for trends) was better than the TG model. At diagnosis, high-risk patients classified at FPR rank 4 and 5 identified 18/22 patients who relapse during the follow-up.

Keywords